Peptides for Immune Support
Research overview of peptides studied for immune function and immunomodulation. Thymosin alpha-1, thymulin, LL-37, and immune peptide evidence.
Research Overview
Immune peptide research includes thymic peptides (thymosin alpha-1, thymulin), antimicrobial peptides (LL-37, defensins), and bioregulators targeting immune function. Several immune peptides have regulatory approval in various countries for specific indications.
Thymosin alpha-1 is among the most studied immune peptides, with approvals in numerous countries for hepatitis B/C treatment and as cancer therapy adjuvant. Its immunomodulatory properties have been documented in multiple clinical trials, though applications beyond approved indications are less supported.
Antimicrobial peptides represent the innate immune system's first line of defense and are being studied for their immunomodulatory properties beyond direct pathogen killing. This research area is evolving rapidly with potential implications for infection control and immune regulation.
Key Immune Peptides
Thymosin Alpha-1 (Tα1)
Status: Approved in 35+ countries
| Indication | Evidence Level |
|---|---|
| Hepatitis B/C | Moderate-High |
| Cancer adjuvant | Moderate |
| Immune deficiency | Moderate |
| General immune support | Low |
The most clinically validated immune peptide with multiple approved indications.
Thymulin
| Aspect | Details |
|---|---|
| Origin | Thymic hormone |
| Mechanism | T-cell modulation |
| Evidence | Low-Moderate |
| Clinical use | Research stage |
LL-37 (Cathelicidin)
| Function | Evidence Level |
|---|---|
| Antimicrobial | Well-established |
| Immunomodulation | Moderate |
| Therapeutic use | Research stage |
Endogenous antimicrobial peptide with documented immune effects.
Thymic Bioregulators
| Peptide | Research Status |
|---|---|
| Thymalin | Approved in Russia |
| Thymogen | Approved in Russia |
| Vilon | Limited human reports; routine immune-support benefit not established |
Russian-developed thymic peptides with varying evidence quality.
For Vilon specifically, human adjunctive-treatment reports exist, but incomplete methods, possible cohort reuse and inadequate safety reporting limit conclusions. These are reports, not a verified number of independent trials. Diabetes report, second diabetes report, colorectal-cancer report. The 2022 gastritis study reported no statistically significant gastric pH change and has unresolved symptom-count inconsistencies. Gastritis report. The 2025 dentistry paper reviews older material rather than reporting a new trial. Dentistry review. Adverse findings in distinct mouse models include increased mammary tumours and reduced survival with synchronous cyclophosphane; they do not quantify human risk, but do not support a blanket safety claim. Mammary-tumour model, mouse combination study.
Antimicrobial Peptides (AMPs)
| Peptide Class | Immune Function |
|---|---|
| Defensins | Innate immunity |
| Cathelicidins | Broad antimicrobial |
| Lactoferricin | Immune modulation |
Evidence Hierarchy
- Best supported: Thymosin alpha-1 (approved indications)
- Moderate support: LL-37 (characterization, mechanism)
- Limited support: Thymulin, thymic bioregulators
- Research stage: Most AMPs for immune modulation
Research Considerations
- “Immune support” is a broad, often vague claim
- Approved indications differ from general immune enhancement
- Many claims extrapolate from in vitro studies
- Bioregulator literature requires careful evaluation
Research context and limitations for Immune Support
Selank
ModerateA synthetic heptapeptide derived from the immunomodulatory peptide tuftsin, developed by Russian researchers and approved in Russia since 2009 for anxiety and neurasthenia. Demonstrates anxiolytic effects comparable to benzodiazepines without sedation, cognitive impairment, or dependence liability. Extensive Russian clinical research supports efficacy, though Western independent replication remains limited.
Kristagen
LowA synthetic tripeptide (Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to regulate thymus function and support immune cell differentiation. No Western clinical validation exists; research is limited to Russian preclinical studies.
Vilon
Clinical certainty not formally gradedLys-Glu (KE) dipeptide with limited human adjunct-treatment reports and experimental cell and animal research. Clinical benefit and safety remain uncertain; animal findings include both favorable and adverse outcomes.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. The peptides listed may or may not have regulatory approval. Always consult a qualified healthcare provider before making any health decisions.